Trials / Completed
CompletedNCT03540615
BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics
Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Increasing Single Oral Doses of BAY1830839 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The primary objectives of this study are to investigate * the safety and tolerability of increasing single oral doses of BAY 1830839 versus placebo under fasted conditions * the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY1830839 | Dose escalation in healthy male subjects |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2018-06-28
- Primary completion
- 2019-02-05
- Completion
- 2019-08-01
- First posted
- 2018-05-30
- Last updated
- 2020-08-05
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03540615. Inclusion in this directory is not an endorsement.